CV Therapeutics rejects buyout offer from Astellas Pharma (updated)

CV Therapeutics, which markets Ranexa (ranolazine), has rejected a buyout bid from Astellas Pharma.

Click here to read the Astellas press release.

Click here to read the response from CV Therapeutics.

Trackbacks

  1. […] CV Therapeutics, the company that manufactures ranolazine (Ranexa) and regadenoson (Lexiscan).   As we reported back in January, CV Therapeutics previously rejected a friendly bid at the same price from Astellas. Astellas […]

Speak Your Mind

*